Hilltop Holdings Inc. Has $946,000 Stock Position in Stryker Corporation $SYK

Hilltop Holdings Inc. lowered its position in Stryker Corporation (NYSE:SYK) by 38.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 2,878 shares of the medical technology company’s stock after selling 1,823 shares during the period. Hilltop Holdings Inc.’s holdings in Stryker were worth $946,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Godfrey Financial Associates Inc. acquired a new position in Stryker in the fourth quarter valued at about $26,000. Sankala Group LLC acquired a new stake in shares of Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker during the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker during the 4th quarter valued at about $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker in the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.1%

Stryker stock opened at $330.69 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The firm has a 50-day moving average of $314.69 and a 200-day moving average of $335.57. The company has a market cap of $126.78 billion, a price-to-earnings ratio of 38.27, a P/E/G ratio of 2.12 and a beta of 0.77. Stryker Corporation has a one year low of $281.00 and a one year high of $404.14.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period last year, the firm earned $2.84 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last 90 days. 4.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SYK. Barclays lowered their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Citigroup reduced their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research report on Friday, May 1st. Wells Fargo & Company dropped their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. cut their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $392.52.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.